Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.
Mariana C. Castells, MD, PhD
Advertisement
Mariana C. Castells, MD, PhD is the director of the drug hypersensitivity and drug desensitization center and the mastocytosis center at Brigham & Women’s Hospital.
Articles by Mariana C. Castells, MD, PhD
Castells describes what’s missing from the current treatment landscape and the potential implications of elenestinib for indolent systemic mastocytosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Obinutuzumab Achieves 95.5% Remission in INS, May Shift Steroid-Sparing Treatment Strategies
3
What Will Precision Dermatology Look Like in Atopic Dermatitis?
4
Why Dermatologists Should Add Serum Tryptase to the Workup for Chronic Itch
5